---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-298441"
form_type: "8-K"
ticker: "JAZZ"
cik: "0001232524"
company_name: "Jazz Pharmaceuticals plc"
filed_at: "2022-12-05T23:59:59+00:00"
generated_at: "2026-06-21T09:26:04.039240+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Jazz acquires exclusive zanidatamab rights from Zymeworks for $50M upfront

## Summary
- Upfront $50M non-refundable cash payment; potential $325M payment after HERIZON-BTC-01 top-line data.
- Regulatory milestones up to $525M; commercial milestones up to $862.5M.
- Tiered royalties of 10%-20% on annual net sales in the Territory.
- Exclusive rights in U.S., Europe, Japan; Asia/Pacific territories excluded per prior BeiGene license.
- Agreement effective Nov 29, 2022 following HSR clearance.

## SEC filing metadata
- accession: 0001193125-22-298441
- form_type: 8-K
- ticker: JAZZ
- cik: 0001232524
- company_name: Jazz Pharmaceuticals plc
- filed_at: 2022-12-05T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1232524/000119312522298441/0001193125-22-298441-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1232524/000119312522298441/d428448d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-298441
- JSON: https://secwatch.observer/filing/0001193125-22-298441.json
- Plain text: https://secwatch.observer/filing/0001193125-22-298441.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.